We undertook a two-stage genome-wide association study (GWAS) of Alzheimer's disease (AD)
involving over 16,000 individuals, the most powerful AD GWAS to date. In stage 1 (3,941 …

Objective: To evaluate CSF levels of β-amyloid (1-42) (Aβ 42 ) alone and in combination with
CSF tau for distinguishing AD from other conditions. Methods: At 10 centers in Europe and …

Importance Cerebral amyloid-β aggregation is an early pathological event in Alzheimer
disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid …

Alzheimer's disease is an age-related progressive neurodegenerative disorder with an
enormous unmet medical need. It is the most common form of dementia affecting ∼5% of adults …

Three sets of research criteria are available for diagnosis of Alzheimer’s disease in subjects
with mild cognitive impairment: the International Working Group-1, International Working …

Creutzfeldt–Jakob disease (CJD) is a rare, fatal, neurodegenerative disease caused by a
transmissible agent designated as proteinaceous infectious agent (prion). Searching for …

Cerebrospinal fluid (CSF) concentrations of amyloid β peptides ending at positions 42 and
40 (Aβ42 and Aβ40, respectively), and total tau (tTau) protein were measured by ELISA in …

We sought to identify new susceptibility loci for Alzheimer's disease through a staged
association study (GERAD+) and by testing suggestive loci reported by the Alzheimer's Disease …

Neurochemical dementia diagnostics (NDD) can significantly improve the clinically based
categorization of patients with early dementia disorders, and the cerebrospinal fluid (CSF) …

In the 12 years since the publication of the first Consensus Paper of the WFSBP on biomarkers
of neurodegenerative dementias, enormous advancement has taken place in the field, …